The Toll-like receptor 4 antagonist TAK-242 protects against chronic pancreatitis in rats
Related Experiment Videos
Long-Fei Pan1, Lei Yu2, Li-Ming Wang1
1Department of Emergency Medicine, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710004, P.R. China.
Abstract:
Chronic pancreatitis is a progressive disease characterized by irreversible morphological changes to the pancreas, typically causing pain and permanent loss of function. It is a poorly understood disease with the pathogenesis remaining unclear. The authors' previous data demonstrated that the inhibition of Toll‑like receptor 4 (TLR4) using TLR4 antagonist kinase (TAK)‑242 attenuates taurocholate‑induced oxidative stress via the regulation of mitochondrial function in the pancreatic acinar cells of mice. In the present study, the effect of TAK‑242 on trinitrobenzene sulfonic acid (TNBS)‑induced chronic pancreatitis was investigated in rats. The results revealed that TAK‑242 attenuated the severity of chronic pancreatic injury, and regulated extracellular matrix secretion and cellular immunity. In addition, TAK‑242 treatment significantly decreased cell apoptosis, as evidenced by the reduction in Terminal deoxynucleotidyl transferase dUTP nick end labeling‑positive cells in pancreas tissue sections, and also promoted cell proliferation in TNBS‑treated animals. Furthermore, the results of the calibrated von Frey filament assay demonstrated that TAK‑242 could prevent the pancreatitis‑induced referred abdominal hypersensitivity. In summary, TAK‑242 exhibits protective effects against TNBS‑induced chronic pancreatitis and may be a potential therapeutic strategy for the treatment of patients with chronic pancreatitis.
Insights
Toll-like receptor 4 (TLR4) antagonist TAK-242 shows protective effects against chronic pancreatitis in rats. This study suggests TAK-242 may be a potential therapeutic strategy for treating chronic pancreatitis.
Area of Science:
- Gastroenterology
- Immunology
- Cell Biology
Background:
- Chronic pancreatitis is a progressive pancreatic disease with unclear pathogenesis.
- Previous studies showed Toll-like receptor 4 (TLR4) inhibition via TAK-242 reduces oxidative stress in pancreatic cells.
- This research investigates TAK-242's effects on trinitrobenzene sulfonic acid (TNBS)-induced chronic pancreatitis.
Purpose of the Study:
- To evaluate the therapeutic potential of TAK-242 in a rat model of chronic pancreatitis.
- To assess TAK-242's impact on pancreatic injury, inflammation, and pain.
- To determine if TAK-242 influences cell apoptosis and proliferation in pancreatitis.
Main Methods:
- Induction of chronic pancreatitis in rats using trinitrobenzene sulfonic acid (TNBS).
- Administration of TAK-242 to assess its therapeutic effects.
- Evaluation of pancreatic injury, extracellular matrix, cellular immunity, apoptosis (TUNEL assay), cell proliferation, and referred abdominal hypersensitivity (von Frey filament assay).
Main Results:
- TAK-242 significantly attenuated the severity of TNBS-induced chronic pancreatitis.
- TAK-242 regulated extracellular matrix secretion and cellular immunity.
- TAK-242 reduced pancreatic cell apoptosis, promoted cell proliferation, and prevented pancreatitis-induced hypersensitivity.
Conclusions:
- TAK-242 demonstrates protective effects against TNBS-induced chronic pancreatitis in rats.
- TAK-242 modulates key pathological processes including inflammation, cell death, and pain signaling.
- TAK-242 represents a potential therapeutic candidate for managing chronic pancreatitis.